Search

Your search keyword '"Giunta, Emilio Francesco"' showing total 196 results
Start Over Author "Giunta, Emilio Francesco"
196 results on '"Giunta, Emilio Francesco"'

2. Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study

Author

Fratino, Lucia, Polesel, Jerry, Giunta, Emilio Francesco, Maruzzo, Marco, Buti, Sebastiano, Hassan, Mona Ali, Basso, Umberto, Rebuzzi, Sara Elena, De Giorgi, Ugo, Cinausero, Marika, Lipari, Helga, Gamba, Teresa, Bimbatti, Davide, Dri, Arianna, Ermacora, Paola, Vignani, Francesca, Fornarini, Giuseppe, Rescigno, Pasquale, and Banna, Giuseppe Luigi

Published
2024
Full Text
View/download PDF

6. Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study

Author

Casadei, Chiara, Scarpi, Emanuela, Conteduca, Vincenza, Gurioli, Giorgia, Cursano, Maria Concetta, Brighi, Nicole, Lolli, Cristian, Schepisi, Giuseppe, Basso, Umberto, Fornarini, Giuseppe, Bleve, Sara, Farolfi, Alberto, Altavilla, Amelia, Burgio, Salvatore Luca, Giunta, Emilio Francesco, Gianni, Caterina, Filograna, Alessia, Ulivi, Paola, Olmos, David, Castro, Elena, and De Giorgi, Ugo

Published
2024
Full Text
View/download PDF

8. The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO network

Author

Giunta, Emilio Francesco, De Padova, Silvia, Anpalakhan, Shobana, De Giorgi, Ugo, Maruzzo, Marco, Rebuzzi, Sara Elena, Cinausero, Marika, Fratino, Lucia, Lipari, Helga, Gamba, Teresa, Bimbatti, Davide, Dri, Arianna, Ermacora, Paola, Vignani, Francesca, Basso, Umberto, Buti, Sebastiano, Gandini, Annalice, Cremante, Malvina, Fornarini, Giuseppe, Rescigno, Pasquale, and Banna, Giuseppe Luigi

Published
2023
Full Text
View/download PDF

9. 68Ga-PSMA PET/CT response and clinical outcomes in patients treated with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective study.

Author

Giunta, Emilio Francesco, primary, Caroli, Paola, additional, Scarpi, Emanuela, additional, Altavilla, Amelia, additional, Marini, Irene, additional, Celli, Monica, additional, Casadei, Chiara, additional, Lolli, Cristian, additional, Schepisi, Giuseppe, additional, Bleve, Sara, additional, Brighi, Nicole, additional, Cursano, Maria Concetta, additional, Martinelli, Giovanni, additional, Matteucci, Federica, additional, and De Giorgi, Ugo, additional

Published
2024
Full Text
View/download PDF

10. Plasma tumour DNA dynamics and circulating subclones patterns in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel in a prospective biomarker trial (NCT03381326).

Author

Brighi, Nicole, primary, Wetterskog, Daniel, additional, Gurioli, Giorgia, additional, Orlando, Francesco, additional, Conteduca, Vincenza, additional, Vainauskas, Osvaldas, additional, Giunta, Emilio Francesco, additional, Bleve, Sara, additional, Casadei, Chiara, additional, Cremaschi, Paolo, additional, Basso, Umberto, additional, Pierantoni, Francesco, additional, Fornarini, Giuseppe, additional, Mosca, Alessandra, additional, Nicodemo, Maurizio, additional, Banna, Giuseppe Luigi, additional, Ulivi, Paola, additional, Demichelis, Francesca, additional, De Giorgi, Ugo, additional, and Attard, Gerhardt, additional

Published
2024
Full Text
View/download PDF

15. A Head-to-Head Comparison of the First-Line Treatments for Locally Advanced or Metastatic Urothelial Cancer: Is There Still a Role for Chemotherapy?

Author

Gasperoni, Lorenzo, Del Bono, Luna, Ossato, Andrea, Giunta, Emilio Francesco, Messori, Andrea, and Damuzzo, Vera

Subjects
CANCER chemotherapy, CANCER prognosis, URINARY organs, ANTINEOPLASTIC agents, DESCRIPTIVE statistics, METASTASIS, SYSTEMATIC reviews, MEDLINE, IMMUNE checkpoint inhibitors, MONOCLONAL antibodies, KAPLAN-Meier estimator, DRUG efficacy, ONLINE information services, QUALITY assurance, DATA analysis software, CONFIDENCE intervals, OVERALL survival
Abstract

Simple Summary: Recently, numerous treatments have been approved for patients with previously untreated locally advanced or metastatic urothelial cancer. These combinations prolong survival compared to chemotherapy, which is generally considered the standard of care. Since direct head-to-head comparisons between these innovative treatments are not available, our analysis was aimed at performing indirect comparisons among these agents, including chemotherapy as a common comparator. In handling these indirect comparisons, our study used an innovative evidence-based method (the IPDfromKM technique) that reconstructs individual patient data from published clinical trials. Overall survival was the endpoint of our analysis. Our results showed that enfortumab vedotin plus pembrolizumab was the most effective treatment at levels of statistical significance. The combinations of a PD(L)-1 inhibitor plus chemotherapy ranked second, while monotherapies with a PD(L)-1 inhibitor ranked third. One strength of this analysis is represented by the large number of different treatments that were evaluated and compared to each other. Background: Patients with locally advanced/metastatic urothelial cancer have been conventionally treated with platinum-based chemotherapy. Recently, numerous new treatments have been proposed to improve overall survival (OS) and reduce adverse effects, but no direct head-to-head comparisons among these agents are available. Methods: The treatments evaluated in our analyses included (a) monotherapy with immune checkpoint inhibitors (ICI); (b) combinations of an ICI with chemotherapy; and (c) combinations of an ICI with other drugs. Using OS as the endpoint, a series of indirect comparisons were performed to rank the most effective regimens against both chemotherapy and each other. Our analysis was based on the application of an artificial intelligence software program (IPDfromKM method) that reconstructs individual patient data from the information reported in the graphs of Kaplan–Meier curves. Results: A total of five studies published in six articles were included. In our main analysis, nivolumab plus chemotherapy showed better OS compared to chemotherapy (HR = 0.70, 95% CI: 0.59–0.82), while durvalumab plus tremelimumab showed no OS benefit (HR = 0.95, 95% CI 0.82–1.11). More interestingly, enfortumab vedotin plus pembrolizumab significantly prolonged OS compared to both chemotherapy alone (HR = 0.53, 95% CI 0.45–0.63) and nivolumab plus chemotherapy (HR = 0.76, 95% CI 0.60–0.97). Discussion and conclusion: Among new treatments for locally advanced and metastatic urothelial cancer, enfortumab vedotin plus pembrolizumab showed the best efficacy in terms of OS. Our results support the use of this combination as a first-line treatment in this setting. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania ‘Luigi Vanvitelli’

Author

De Falco, Vincenzo, Poliero, Luca, Vitiello, Pietro Paolo, Ciardiello, Davide, Vitale, Pasquale, Zanaletti, Nicoletta, Giunta, Emilio Francesco, Terminiello, Marinella, Caputo, Vincenza, Carlino, Francesca, Di Liello, Raimondo, Ventriglia, Anna, Famiglietti, Vincenzo, Martinelli, Erika, Morgillo, Floriana, Orditura, Michele, De Vita, Ferdinando, Fasano, Morena, Napolitano, Stefania, Martini, Giulia, Della Corte, Carminia Maria, Franco, Renato, Altucci, Lucia, Ciardiello, Fortunato, and Troiani, Teresa

Published
2020
Full Text
View/download PDF

18. Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer

Author

Vitiello, Pietro Paolo, Martini, Giulia, Mele, Luigi, Giunta, Emilio Francesco, De Falco, Vincenzo, Ciardiello, Davide, Belli, Valentina, Cardone, Claudia, Matrone, Nunzia, Poliero, Luca, Tirino, Virginia, Napolitano, Stefania, Della Corte, Carminia, Selvaggi, Francesco, Papaccio, Gianpaolo, Troiani, Teresa, Morgillo, Floriana, Desiderio, Vincenzo, Ciardiello, Fortunato, and Martinelli, Erika

Published
2021
Full Text
View/download PDF

20. Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature

Author

Viscardi, Giuseppe, Zanaletti, Nicoletta, Ferrara, Maria Giovanna, Sica, Antonello, Falcone, Umberto, Guastafierro, Salvatore, Bracale, Umberto, Ribero, Dario, Fasano, Morena, Napolitano, Stefania, Vitale, Pasquale, De Falco, Vincenzo, Giunta, Emilio Francesco, Martinelli, Erika, Ciardiello, Davide, Ciardiello, Fortunato, and Troiani, Teresa

Published
2019
Full Text
View/download PDF

23. Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer

Author

Cursano, Maria Concetta, primary, Giunta, Emilio Francesco, additional, Scarpi, Emanuela, additional, Casadei, Chiara, additional, Virga, Alessandra, additional, Ulivi, Paola, additional, Bleve, Sara, additional, Brighi, Nicole, additional, Ravaglia, Giorgia, additional, Pantano, Francesco, additional, Conteduca, Vincenza, additional, Santini, Daniele, additional, and De Giorgi, Ugo, additional

Published
2023
Full Text
View/download PDF

24. Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis

Author

Messina, Carlo, primary, Giunta, Emilio Francesco, additional, Signori, Alessio, additional, Rebuzzi, Sara Elena, additional, Banna, Giuseppe Luigi, additional, Maniam, Akash, additional, Buti, Sebastiano, additional, Cattrini, Carlo, additional, Fornarini, Giuseppe, additional, Bauckneht, Matteo, additional, Greystoke, Alastair, additional, Plummer, Ruth, additional, Oing, Christoph, additional, and Rescigno, Pasquale, additional

Published
2023
Full Text
View/download PDF

26. Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype

Author

Ciardiello, Davide, Blauensteiner, Bernadette, Matrone, Nunzia, Belli, Valentina, Mohr, Thomas, Vitiello, Pietro Paolo, Martini, Giulia, Poliero, Luca, Cardone, Claudia, Napolitano, Stefania, De Falco, Vincenzo, Giunta, Emilio Francesco, Ciaramella, Vincenza, Corte, Carminia della, Barra, Giusi, Selvaggi, Francesco, Franco, Renato, Marino, Federica Zito, Cuomo, Antonio, Morgillo, Floriana, Troiani, Teresa, Sibilia, Maria, Ciardiello, Fortunato, and Martinelli, Erika

Published
2021
Full Text
View/download PDF

28. Impact of somatic DNA repair mutations on bone-related efficacy endpoints in patients with metastatic castration-resistant prostate cancer (mCRPC): A retrospective analysis.

Author

Cursano, Maria Concetta, primary, Giunta, Emilio Francesco, additional, Scarpi, Emanuela, additional, Casadei, Chiara, additional, Virga, Alessandra, additional, Ulivi, Paola, additional, Bleve, Sara, additional, Brighi, Nicole, additional, Ravaglia, Giorgia, additional, Pantano, Francesco, additional, Santini, Daniele, additional, Conteduca, Vincenza, additional, and De Giorgi, Ugo, additional

Published
2023
Full Text
View/download PDF

29. Impact of 68Ga-PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide.

Author

Altavilla, Amelia, primary, Caroli, Paola, additional, Giunta, Emilio Francesco, additional, Scarpi, Emanuela, additional, Rossetti, Virginia, additional, Casadei, Chiara, additional, Lolli, Cristian, additional, Schepisi, Giuseppe, additional, Bleve, Sara, additional, Cursano, Maria Concetta, additional, Gasperoni, Lorenzo, additional, Matteucci, Federica, additional, and De Giorgi, Ugo, additional

Published
2023
Full Text
View/download PDF

34. The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network

Author

Banna, Giuseppe Luigi, primary, Basso, Umberto, additional, Giunta, Emilio Francesco, additional, Fratino, Lucia, additional, Rebuzzi, Sara Elena, additional, Buti, Sebastiano, additional, Maruzzo, Marco, additional, De Giorgi, Ugo, additional, Murianni, Veronica, additional, Cinausero, Marika, additional, Lipari, Helga, additional, Gamba, Teresa, additional, Caffo, Orazio, additional, Bimbatti, Davide, additional, Dri, Arianna, additional, Mosca, Alessandra, additional, Ermacora, Paola, additional, Vignani, Francesca, additional, Msaki, Aichi, additional, Bonifacio, Barbara, additional, Lombardo, Valentina, additional, Conteduca, Vincenza, additional, Fornarini, Giuseppe, additional, and Rescigno, Pasquale, additional

Published
2022
Full Text
View/download PDF

35. A novel immunotherapy prognostic score for patients with pretreated advanced urinary tract carcinoma from the subgroup analysis of the SAUL study. The urInary TrAct CArcinoma score (ITACA)

Author

Fornarini, Giuseppe, primary, Rebuzzi, Sara Elena, additional, Buti, Sebastiano, additional, Rescigno, Pasquale, additional, Merseburger, Axel, additional, de Giorgi, Ugo, additional, Basso, Umberto, additional, Maruzzo, Marco, additional, Giannatempo, Patrizia, additional, Ponzano, Marta, additional, Giunta, Emilio Francesco, additional, Catalano, Fabio, additional, Murianni, Veronica, additional, Damassi, Alessandra, additional, Cremante, Malvina, additional, Gandini, Annalice, additional, Puglisi, Silvia, additional, Obispo, Miguel Angel Llaja, additional, Signori, Alessio, additional, and Banna, Giuseppe Luigi, additional

Published
2022
Full Text
View/download PDF

36. Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network

Author

Rescigno, Pasquale, primary, Maruzzo, Marco, additional, Rebuzzi, Sara Elena, additional, Murianni, Veronica, additional, Cinausero, Marika, additional, Lipari, Helga, additional, Fratino, Lucia, additional, Gamba, Teresa, additional, De Giorgi, Ugo, additional, Caffo, Orazio, additional, Bimbatti, Davide, additional, Dri, Arianna, additional, Mosca, Alessandra, additional, Giunta, Emilio Francesco, additional, Ermacora, Paola, additional, Vignani, Francesca, additional, Msaki, Aichi, additional, Bonifacio, Barbara, additional, Lombardo, Valentina, additional, Conteduca, Vincenza, additional, Basso, Umberto, additional, Fornarini, Giuseppe, additional, and Banna, Giuseppe Luigi, additional

Published
2022
Full Text
View/download PDF

38. Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR

Author

Giunta, Emilio Francesco, primary, De Falco, Vincenzo, additional, Vitiello, Pietro Paolo, additional, Guerrera, Luigi Pio, additional, Suarato, Gabriella, additional, Napolitano, Rossella, additional, Perrone, Alessandra, additional, Argenziano, Giuseppe, additional, Franco, Renato, additional, Caraglia, Michele, additional, Martinelli, Erika, additional, Ciardiello, Davide, additional, Ciardiello, Fortunato, additional, Napolitano, Stefania, additional, and Troiani, Teresa, additional

Published
2022
Full Text
View/download PDF

41. Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials

Author

Banna, Giuseppe Luigi, primary, Signori, Alessio, additional, Curioni-Fontecedro, Alessandra, additional, Cortellini, Alessio, additional, Ponzano, Marta, additional, Giunta, Emilio Francesco, additional, Rebuzzi, Sara Elena, additional, Chan, Samuel, additional, Gebbia, Vittorio, additional, van Eeden, Ronwyn, additional, Addeo, Alfredo, additional, and Ottensmeier, Christian, additional

Published
2022
Full Text
View/download PDF

42. Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas

Author

Ottaviano, Margaret, primary, Giunta, Emilio Francesco, additional, Marandino, Laura, additional, Tortora, Marianna, additional, Attademo, Laura, additional, Bosso, Davide, additional, Cardalesi, Cinzia, additional, Fabbrocini, Antonietta, additional, Rosanova, Mario, additional, Silvestri, Antonia, additional, Montella, Liliana, additional, Tammaro, Pasquale, additional, Marra, Ester, additional, Trojaniello, Claudia, additional, Vitale, Maria Grazia, additional, Simeone, Ester, additional, Troiani, Teresa, additional, Daniele, Bruno, additional, and Ascierto, Paolo Antonio, additional

Published
2022
Full Text
View/download PDF

43. Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence

Author

Rebuzzi, Sara Elena, primary, Banna, Giuseppe Luigi, additional, Murianni, Veronica, additional, Damassi, Alessandra, additional, Giunta, Emilio Francesco, additional, Fraggetta, Filippo, additional, De Giorgi, Ugo, additional, Cathomas, Richard, additional, Rescigno, Pasquale, additional, Brunelli, Matteo, additional, and Fornarini, Giuseppe, additional

Published
2021
Full Text
View/download PDF

44. Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients.

Author

Giunta, Emilio Francesco, Caroli, Paola, Scarpi, Emanuela, Altavilla, Amelia, Rossetti, Virginia, Marini, Irene, Celli, Monica, Casadei, Chiara, Lolli, Cristian, Schepisi, Giuseppe, Bleve, Sara, Brighi, Nicole, Cursano, Maria Concetta, Paganelli, Giovanni, Matteucci, Federica, and De Giorgi, Ugo

Subjects
*CASTRATION-resistant prostate cancer, *PROSTATE cancer patients, *PROSTATE-specific antigen, *SURVIVAL analysis (Biometry), *REGRESSION analysis
Abstract

Purpose: to assess the utility of response monitoring to enzalutamide by using [68Ga]Ga-PSMA PET in mCRPC patients treated with enzalutamide as first-line therapy.patients underwent [68Ga]Ga-PSMA PET less than 8 weeks before and 3 months after starting enzalutamide. On the basis of EAU/EANM criteria, patients were categorized as PSMA responders (PET-R) or PSMA non-responders (PET-NR), whilst, based on PSA, they were classified as biochemical responders (PSA-R) or non-responders (PSA-NR). Survival analysis was performed using the Cox regression hazard model and the Kaplan-Meier method.69 patients were considered fully evaluable. We observed 47.8% of concordance between [68Ga]Ga-PSMA PET and PSA monitoring at 3 months after starting enzalutamide. For discordant cases, the PSA reduction has a weak impact on PFS and a significant impact on OS in PET-NR patients, whilst this change has no impact either for PFS and OS in PET-R ones.[68Ga]Ga-PSMA PET could be a useful imaging tool for monitoring response to enzalutamide in mCRPC patients, being more informative than PSA in this setting, and possibly better guiding clinicians in therapeutic decisions.Methods: to assess the utility of response monitoring to enzalutamide by using [68Ga]Ga-PSMA PET in mCRPC patients treated with enzalutamide as first-line therapy.patients underwent [68Ga]Ga-PSMA PET less than 8 weeks before and 3 months after starting enzalutamide. On the basis of EAU/EANM criteria, patients were categorized as PSMA responders (PET-R) or PSMA non-responders (PET-NR), whilst, based on PSA, they were classified as biochemical responders (PSA-R) or non-responders (PSA-NR). Survival analysis was performed using the Cox regression hazard model and the Kaplan-Meier method.69 patients were considered fully evaluable. We observed 47.8% of concordance between [68Ga]Ga-PSMA PET and PSA monitoring at 3 months after starting enzalutamide. For discordant cases, the PSA reduction has a weak impact on PFS and a significant impact on OS in PET-NR patients, whilst this change has no impact either for PFS and OS in PET-R ones.[68Ga]Ga-PSMA PET could be a useful imaging tool for monitoring response to enzalutamide in mCRPC patients, being more informative than PSA in this setting, and possibly better guiding clinicians in therapeutic decisions.Results: to assess the utility of response monitoring to enzalutamide by using [68Ga]Ga-PSMA PET in mCRPC patients treated with enzalutamide as first-line therapy.patients underwent [68Ga]Ga-PSMA PET less than 8 weeks before and 3 months after starting enzalutamide. On the basis of EAU/EANM criteria, patients were categorized as PSMA responders (PET-R) or PSMA non-responders (PET-NR), whilst, based on PSA, they were classified as biochemical responders (PSA-R) or non-responders (PSA-NR). Survival analysis was performed using the Cox regression hazard model and the Kaplan-Meier method.69 patients were considered fully evaluable. We observed 47.8% of concordance between [68Ga]Ga-PSMA PET and PSA monitoring at 3 months after starting enzalutamide. For discordant cases, the PSA reduction has a weak impact on PFS and a significant impact on OS in PET-NR patients, whilst this change has no impact either for PFS and OS in PET-R ones.[68Ga]Ga-PSMA PET could be a useful imaging tool for monitoring response to enzalutamide in mCRPC patients, being more informative than PSA in this setting, and possibly better guiding clinicians in therapeutic decisions.Conclusions: to assess the utility of response monitoring to enzalutamide by using [68Ga]Ga-PSMA PET in mCRPC patients treated with enzalutamide as first-line therapy.patients underwent [68Ga]Ga-PSMA PET less than 8 weeks before and 3 months after starting enzalutamide. On the basis of EAU/EANM criteria, patients were categorized as PSMA responders (PET-R) or PSMA non-responders (PET-NR), whilst, based on PSA, they were classified as biochemical responders (PSA-R) or non-responders (PSA-NR). Survival analysis was performed using the Cox regression hazard model and the Kaplan-Meier method.69 patients were considered fully evaluable. We observed 47.8% of concordance between [68Ga]Ga-PSMA PET and PSA monitoring at 3 months after starting enzalutamide. For discordant cases, the PSA reduction has a weak impact on PFS and a significant impact on OS in PET-NR patients, whilst this change has no impact either for PFS and OS in PET-R ones.[68Ga]Ga-PSMA PET could be a useful imaging tool for monitoring response to enzalutamide in mCRPC patients, being more informative than PSA in this setting, and possibly better guiding clinicians in therapeutic decisions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Additional file 1 of Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer

Author

Vitiello, Pietro Paolo, Martini, Giulia, Mele, Luigi, Giunta, Emilio Francesco, Falco, Vincenzo De, Ciardiello, Davide, Belli, Valentina, Cardone, Claudia, Matrone, Nunzia, Poliero, Luca, Tirino, Virginia, Napolitano, Stefania, Carminia Della Corte, Selvaggi, Francesco, Papaccio, Gianpaolo, Troiani, Teresa, Morgillo, Floriana, Desiderio, Vincenzo, Ciardiello, Fortunato, and Martinelli, Erika

Abstract

Additional file 1: Supplementary table 1. Detailed values for combination index for each cell line and each niraparib + chemotherapeutics combination across 3 Effective Doses (EDs). ED50, ED75, and ED90 represent the required dose levels able to decrease cell viability to 50, 75, or 90%, respectively.

Published
2021
Full Text
View/download PDF

49. Additional file 3 of Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer

Author

Vitiello, Pietro Paolo, Martini, Giulia, Mele, Luigi, Giunta, Emilio Francesco, Falco, Vincenzo De, Ciardiello, Davide, Belli, Valentina, Cardone, Claudia, Matrone, Nunzia, Poliero, Luca, Tirino, Virginia, Napolitano, Stefania, Carminia Della Corte, Selvaggi, Francesco, Papaccio, Gianpaolo, Troiani, Teresa, Morgillo, Floriana, Desiderio, Vincenzo, Ciardiello, Fortunato, and Martinelli, Erika

Abstract

Additional file 3: Supplementary table 3. BRCA2 mutations in the cell panel. Functional prediction according to FATHMM algorithm for COSMIC-identified non-synonymous, frameshift or truncating mutations of BRCA2 in our panel. Whenever available, Leiden Open Variant Database (LOVD) reference is also included [last accessed July 1st 2020].

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results